Among 95 patients who are overweight or obese, an experimental daily pill from Novo Nordisk reduced their mean body weight by 13.1%, NBC News reported Sept. 10.
GLP-1s
Patients who took semaglutide, the main ingredient of Wegovy and Ozempic, died less often from COVID-19 compared to those who took a placebo, according to a study published Aug. 30 in the Journal of the American College of Cardiology.
Employers and employees spent more than $400 billion on obesity care in 2023; Novo Nordisk's CEO said weight loss drug Wegovy can reduce these costs — an inverse of critics' expectations.
Many cardiac drugs have notoriously low adherence rates, but GLP-1s may be overcoming that problem, according to Northwell Health cardiologist, Jeffrey Wessler, MD.
There's no shortage of headlines and hypotheticals about the blockbuster drug class of GLP-1s. Stephen Klasko, MD, argues we're asking the wrong questions about GLP-1s.
Advertisement
As experts forecast GLP-1 medications boosting national economies, the manufacturers of these popular drugs have reported fruitful second quarters.
Nearly half of online pharmacies that sell semaglutide — the active ingredient in Ozempic and Wegovy — are doing so illegally, posing safety risks for consumers, according to a study published Aug. 2 in JAMA Network Open.
There has been an uptick in patients being treated for eating disorders who are abusing GLP-1 drugs like Ozempic, Mounjaro and Wegovy, according to research published Aug. 1 in the Journal of Clinical Psychopharmacology.
A GLP-1 medication might protect against dementia, according to researchers of a phase 2 trial that found liraglutide could slow cognitive decline by 18% after one year of use.
Up to 30% of GLP-1 medications are acquired by patients through compounding pharmacies instead of the weight loss drugs' manufacturers like Novo Nordisk or Eli Lilly, according to KFF Health News.